Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress

Site Image

Study Overview

Only patients admitted to the hospital are eligible to participate.

The main purpose of this research is to determine whether mesenchymal stromal stem cells are effective and safe in helping patients with moderate to severe ARDS due to COVID-19 infection. 

Study Description

This is a study of investigational mesenchymal stromal cells (MSC) for the treatment of acute respiratory distress syndrome (ARDS) in patients with COVID-19, the infection due to the 2019 novel coronavirus.  The study will enroll 240 patients who will receive either MSC or placebo (an inactive substance). Patients will choose to participate in this study will receive two infusions of either MSC or placebo and will be followed during the course of their stay in the hospital and periodically for up to 1 year after enrollment in the trial. After hospital discharge, all follow-up contacts will be conducted via telephone.

  • Study Identifier: 842986

Recruitment Status

Enrolling By Invitation

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu